TY - JOUR
T1 - Chemoenzymatic synthesis with distinct Pasteurella heparosan synthases
T2 - Monodisperse polymers and unnatural structures
AU - Sismey-Ragatz, Alison E.
AU - Green, Dixy E.
AU - Otto, Nigel J.
AU - Rejzek, Martin
AU - Field, Robert A.
AU - DeAngelis, Paul L.
PY - 2007/9/28
Y1 - 2007/9/28
N2 - Heparosan (-GlcUA-β1,4-GlcNAc-α1,4-)n is a member of the glycosaminoglycan polysaccharide family found in the capsule of certain pathogenic bacteria as well as the precursor for the vertebrate polymers, heparin and heparan sulfate. The two heparosan synthases from the Gram-negative bacteria Pasteurella multocida, PmHS1 and PmHS2, were efficiently expressed and purified using maltose-binding protein fusion constructs. These relatively homologous synthases displayed distinct catalytic characteristics. PmHS1, but not PmHS2, was able to produce large molecular mass (100-800 kDa) monodisperse polymers in synchronized, stoichiometrically controlled reactions in vitro. PmHS2, but not PmHS1, was able to utilize many unnatural UDP-sugar analogs (including substrates with acetamido-containing uronic acids or longer acyl chain hexosamine derivatives) in vitro. Overall these findings reveal potential differences in the active sites of these two Pasteurella enzymes. In the future, these catalysts should allow the creation of a variety of heparosan and heparinoids with utility for medical applications.
AB - Heparosan (-GlcUA-β1,4-GlcNAc-α1,4-)n is a member of the glycosaminoglycan polysaccharide family found in the capsule of certain pathogenic bacteria as well as the precursor for the vertebrate polymers, heparin and heparan sulfate. The two heparosan synthases from the Gram-negative bacteria Pasteurella multocida, PmHS1 and PmHS2, were efficiently expressed and purified using maltose-binding protein fusion constructs. These relatively homologous synthases displayed distinct catalytic characteristics. PmHS1, but not PmHS2, was able to produce large molecular mass (100-800 kDa) monodisperse polymers in synchronized, stoichiometrically controlled reactions in vitro. PmHS2, but not PmHS1, was able to utilize many unnatural UDP-sugar analogs (including substrates with acetamido-containing uronic acids or longer acyl chain hexosamine derivatives) in vitro. Overall these findings reveal potential differences in the active sites of these two Pasteurella enzymes. In the future, these catalysts should allow the creation of a variety of heparosan and heparinoids with utility for medical applications.
UR - http://www.scopus.com/inward/record.url?scp=35348988601&partnerID=8YFLogxK
U2 - 10.1074/jbc.M701599200
DO - 10.1074/jbc.M701599200
M3 - Article
C2 - 17627940
AN - SCOPUS:35348988601
VL - 282
SP - 28321
EP - 28327
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
SN - 0021-9258
IS - 39
ER -